Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

Annals of Hematology

Volumn 90, Issue 8, 2011, Pages 917-931

  Wang, Ai Hua ^a   Wei, Lin ^a   Chen, Li ^a   Zhao, Shu Qing ^a   Wu, Wei Li ^a   Shen, Zhi Xiang ^a   Li, Jun Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute myeloid leukemia; Bortezomib; Myelodysplastic syndrome; Valproic acid

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOCHONDRIAL MEMBRANE POTENTIAL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PYRAZINES; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 79960279715     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1175-6     Document Type: Article

References (40)

1. A Hershko A Ciechanover 1998 The ubiquitin system Annu Rev Biochem 67 425 479 9759494 10.1146/annurev.biochem.67.1.425 1:CAS:528:DyaK1cXlsFOmsLc%3D (Pubitemid 28411135)
2. M Muratani WP Tansey 2003 How the ubiquitin-proteasome system controls transcription Nat Rev Mol Cell Biol 4 192 201 12612638 10.1038/nrm1049 1:CAS:528:DC%2BD3sXhsFajsLw%3D (Pubitemid 36288041)
3. KC Anderson 2009 Proteasome inhibitors in multiple myeloma Semin Oncol 36 S20 S26 19393832 10.1053/j.seminoncol.2009.02.001 1:CAS:528: DC%2BD1MXmt1Gmur4%3D
4. J Adams VJ Palombella PJ Elliott 2000 Proteasome inhibition: a new strategy in cancer treatment Invest New Drugs 18 109 121 10857991 10.1023/A:1006321828515 1:CAS:528:DC%2BD3cXkt1CntLc%3D (Pubitemid 30261285)
5. AM Roccaro T Hideshima PG Richardson D Russo D Ribatti A Vacca F Dammacco KC Anderson 2006 Bortezomib as an antitumor agent Curr Pharm Biotechnol 7 441 448 17168660 10.2174/138920106779116865 1:CAS:528:DC%2BD2sXmsFCgsg%3D%3D (Pubitemid 46017535)
6. J Adams 2002 Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer Curr Opin Chem Biol 6 493 500 12133726 10.1016/S1367-5931(02)00343-5 1:CAS:528:DC%2BD38XlsVyjur0%3D (Pubitemid 34804773)
7. R LeBlanc LP Catley T Hideshima S Lentzsch CS Mitsiades N Mitsiades D Neuberg O Goloubeva CS Pien J Adams D Gupta PG Richardson NC Munshi KC Anderson 2002 Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Res 62 4996 5000 12208752 1:CAS:528:DC%2BD38Xmslyksrw%3D (Pubitemid 34984425)
8. S Gatto B Scappini L Pham F Onida M Milella G Ball C Ricci V Divoky S Verstovsek HM Kantarjian MJ Keating JE Cortes-Franco M Beran 2003 The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate Haematologica 88 853 863 12935973 1:CAS:528:DC%2BD3sXovVGhs7c%3D (Pubitemid 37128085)
9. TW Kelley S Alkan G Srkalovic ED Hsi 2004 Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis Leuk Res 28 845 850 15203282 10.1016/j.leukres.2003.12.010 1:CAS:528:DC%2BD2cXltVCrsLc%3D (Pubitemid 38760046)
10. B Zheng GV Georgakis Y Li A Bharti D McConkey BB Aggarwal A Younes 2004 Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors Clin Cancer Res 10 3207 3215 15131062 10.1158/1078-0432.CCR-03-0494 1:CAS:528:DC%2BD2cXjs12lt7k%3D (Pubitemid 38619702)
11. E Colado S Alvarez-Fernandez P Maiso J Martin-Sanchez MB Vidriales M Garayoa EM Ocio JC Montero A Pandiella JF San Miguel 2008 The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype Haematologica 93 57 66 18166786 10.3324/haematol.11666 1:CAS:528:DC%2BD1cXitVOhsrs%3D (Pubitemid 351156152)
12. C Stapnes AP Doskeland K Hatfield E Ersvaer A Ryningen JB Lorens BT Gjertsen O Bruserud 2007 The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells Br J Haematol 136 814 828 17341267 10.1111/j.1365-2141.2007. 06504.x 1:CAS:528:DC%2BD2sXmt1Gns7c%3D (Pubitemid 46348414)
13. E Terpos E Verrou A Banti V Kaloutsi A Lazaridou K Zervas 2007 Bortezomib is an effective agent for MDS/MPD syndrome with 5q-anomaly and thrombocytosis Leuk Res 31 559 562 16820206 10.1016/j.leukres.2006.05.018 1:CAS:528: DC%2BD2sXhs1SksbY%3D (Pubitemid 46198932)
14. N Mitsiades CS Mitsiades PG Richardson C McMullan V Poulaki G Fanourakis R Schlossman D Chauhan NC Munshi T Hideshima VM Richon PA Marks KC Anderson 2003 Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 4055 4062 12531799 10.1182/blood-2002-11-3514 1:CAS:528: DC%2BD3sXktVGnu7w%3D (Pubitemid 36857886)
15. LZ He T Tolentino P Grayson S Zhong RP Warrell Jr RA Rifkind PA Marks VM Richon PP Pandolfi 2001 Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia J Clin Invest 108 1321 1330 11696577 1:CAS:528:DC%2BD3MXot12kt7Y%3D (Pubitemid 33107760)
16. PA Marks VM Richon R Breslow RA Rifkind 2001 Histone deacetylase inhibitors as new cancer drugs Curr Opin Oncol 13 477 483 11673688 10.1097/00001622-200111000-00010 1:CAS:528:DC%2BD3MXos1Oqs7s%3D (Pubitemid 33027900)
17. C Gridelli A Rossi P Maione 2008 The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer Crit Rev Oncol Hematol 68 29 36 18424067 10.1016/j.critrevonc.2008.03.002
18. L Yin G Laevsky C Giardina 2001 Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity J Biol Chem 276 44641 44646 11572859 10.1074/jbc.M105170200 1:CAS:528:DC%2BD3MXovFegt7o%3D
19. U Heider I von Metzler M Kaiser M Rosche J Sterz S Rotzer J Rademacher C Jakob C Fleissner U Kuckelkorn PM Kloetzel O Sezer 2008 Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma Eur J Haematol 80 133 142 18005386 10.1111/j.1600-0609.2007.00995.x 1:CAS:528:DC%2BD1cXivFahsbg%3D
20. XY Pei Y Dai S Grant 2004 Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 3839 3852 15173093 10.1158/1078-0432.CCR-03-0561 1:CAS:528:DC%2BD2cXksVKnt7g%3D (Pubitemid 38697620)
21. C Yu M Rahmani D Conrad M Subler P Dent S Grant 2003 The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 Blood 102 3765 3774 12893773 10.1182/blood-2003-03-0737 1:CAS:528:DC%2BD3sXptVymtb0%3D (Pubitemid 37409399)
22. QL Zhang L Wang YW Zhang XX Jiang F Yang WL Wu A Janin Z Chen ZX Shen SJ Chen WL Zhao 2009 The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 1507 1514 19282831 10.1038/leu.2009.41 1:CAS:528:DC%2BD1MXpvF2kurk%3D
23. A Badros AM Burger S Philip R Niesvizky SS Kolla O Goloubeva C Harris J Zwiebel JJ Wright I Espinoza-Delgado MR Baer JL Holleran MJ Egorin S Grant 2009 Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 5250 5257 19671864 10.1158/1078-0432.CCR-08-2850 1:CAS:528:DC%2BD1MXpvFeit7Y%3D
24. R Kawagoe H Kawagoe K Sano 2002 Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways Leuk Res 26 495 502 11916526 10.1016/S0145-2126(01)00151-5 1:CAS:528:DC%2BD38XitlaksLk%3D (Pubitemid 34251096)
25. YC Cheng H Lin MJ Huang JM Chow S Lin HE Liu 2007 Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia Leuk Res 31 1403 1411 17445886 10.1016/j.leukres. 2007.03.012 1:CAS:528:DC%2BD2sXovFKntb0%3D (Pubitemid 47212434)
26. IV Ulasov S Nandi M Dey AM Sonabend MS Lesniak 2010 Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy Mol Med 17 103 112 20957337
27. Z Metting LA Rodiger RE Stewart M Oudkerk J De Keyser J van der Naalt 2009 Perfusion computed tomography in the acute phase of mild head injury: regional dysfunction and prognostic value Ann Neurol 66 809 816 20035508 10.1002/ana.21785
28. LE Glover K Newton G Krishnan R Bronson A Boyle LS Krivickas RH Brown Jr 2010 Dysferlin overexpression in skeletal muscle produces a progressive myopathy Ann Neurol 67 384 393 20373350 1:CAS:528:DC%2BC3cXlsFSltL8%3D
29. C Perier J Bove B Dehay V Jackson-Lewis PS Rabinovitch S Przedborski M Vila 2010 Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins Ann Neurol 68 184 192 20695011 1:CAS:528: DC%2BC3cXhtFWgsLrL
30. S Arbogast M Beuvin B Fraysse H Zhou F Muntoni A Ferreiro 2009 Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment Ann Neurol 65 677 686 19557870 10.1002/ana.21644 1:CAS:528:DC%2BD1MXpt1Onsbg%3D
31. AA Kazi CH Lang 2010 PRAS40 regulates protein synthesis and cell cycle in C2C12 myoblasts Mol Med 16 359 371 20464060 10.2119/molmed.2009-00168 1:CAS:528:DC%2BC3cXhtFKlt7bE
32. Y Fan F Shen T Frenzel W Zhu J Ye J Liu Y Chen H Su WL Young GY Yang 2010 Endothelial progenitor cell transplantation improves long-term stroke outcome in mice Ann Neurol 67 488 497 20437584 10.1002/ana.21919 1:CAS:528: DC%2BC3cXntFCru7c%3D
33. A Fribley Q Zeng CY Wang 2004 Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells Mol Cell Biol 24 9695 9704 15509775 10.1128/MCB.24.22.9695-9704.2004 1:CAS:528:DC%2BD2cXpslOntrY%3D (Pubitemid 39458799)
34. PX Yuan LD Huang YM Jiang JS Gutkind HK Manji G Chen 2001 The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth J Biol Chem 276 31674 31683 11418608 10.1074/jbc.M104309200 1:CAS:528:DC%2BD3MXms1Smsro%3D
35. M Kaiser I Zavrski J Sterz C Jakob C Fleissner PM Kloetzel O Sezer U Heider 2006 The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma Haematologica 91 248 251 16461312 1:CAS:528:DC%2BD28XisFWrsLY%3D
36. A Kuendgen N Gattermann 2007 Valproic acid for the treatment of myeloid malignancies Cancer 110 943 954 17647267 10.1002/cncr.22891 1:CAS:528: DC%2BD2sXhtVChs7bE (Pubitemid 47312858)
37. T Jabs 1999 Reactive oxygen intermediates as mediators of programmed cell death in plants and animals Biochem Pharmacol 57 231 245 9890550 10.1016/S0006-2952(98)00227-5 1:CAS:528:DyaK1MXitV2mtA%3D%3D (Pubitemid 29056201)
38. C Nishioka T Ikezoe J Yang HP Koeffler A Yokoyama 2008 Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell Leukemia 22 1449 1452 18185526 10.1038/sj.leu.2405079 1:CAS:528:DC%2BD1cXosFSmsL4%3D (Pubitemid 352006093)
39. C Yu G Dasmahapatra P Dent S Grant 2005 Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells Leukemia 19 1579 1589 16015388 10.1038/sj.leu.2403868 1:CAS:528: DC%2BD2MXovVOjurk%3D (Pubitemid 43090402)
40. T Braun G Carvalho A Coquelle MC Vozenin P Lepelley F Hirsch JJ Kiladjian V Ribrag P Fenaux G Kroemer 2006 NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome Blood 107 1156 1165 16223780 10.1182/blood-2005-05-1989 1:CAS:528:DC%2BD28Xht1OntLs%3D (Pubitemid 43156318)